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Purpose of review
Mitochondrial diseases are a major category of childhood illness that produce a wide
variety of symptoms and multisystemic disorders. This review highlights recent clinically
important developments in diagnostic evaluation and treatment of mitochondrial
diseases.
Recent findings
Major advances have been made in understanding the genetic bases of mitochondrial
diseases. Molecular defects have recently been reported in mitochondrial DNA
maintenance, RNA translation and protein import and in mitochondrial fusion and fission,
opening new areas of cell disorder. Diagnostic testing is struggling to keep pace with
these fundamental discoveries. The diagnostic approach to children suspected of
mitochondrial disease is rapidly evolving but few patients have a molecular diagnosis. A
better notion of the prognosis of affected children is emerging from studies of long-term
outcome. Some therapeutic successes are reported, such as in coenzyme Q deficiency
conditions.
Summary
Mitochondrial diseases can present with signs in almost any organ.Well planned clinical
evaluation is the key to successful diagnostic work-up of mitochondrial diseases. An
approach is presented for further testing in specialized laboratories. Mitochondrial
diseases can be caused by mutations in mitochondrial DNA or, more commonly in
children, in nuclear genes. Mitochondrial DNA mutations pose special challenges for
genetic counseling and prenatal diagnosis. Supportive treatment and avoidance of
environmental stresses are important aspects of patient care. Specific treatment of
mitochondrial diseases is in its infancy and is a major challenge for pediatric medicine.
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1040-8703Introduction
Mitochondrial diseases are a groupof inheriteddisorders of
energy metabolism associated with a vast range of pre-
sentations, symptoms, severity and outcome. Combined,
they form one of the commonest groups of inherited
metabolic diseases, with a minimum birth prevalence
estimated at approximately 1/5000 [1,2,3]. Because oxi-
dative phosphorylation (OXPHOS) is necessary for nearly
all cells, any organ can be affected in mitochondrial dis-
eases. Mitochondrial diseases may present to numerous
pediatric subspecialists and are included in the differential
diagnoses of a large number of clinical situations. As yet,
few affected patients have a definite molecular diagnosis.
The present review concentrates on recent advances of
clinical importance in pediatrics. The challenges for the
pediatrician are as follows: which patients should be
investigated? The answer to this question requiresopyright © Lippincott Williams & Wilkins. Unauth
1040-8703  2008 Wolters Kluwer Health | Lippincott Williams & Wilkinsknowledge of the clinical spectrum of mitochondrial
diseases. How? Among several specialized, often invasive
tests, which is best, when, and in which tissue? How will
diagnosis and treatment help the patient?Mitochondrial genetics and biology
About 10–15% of mitochondrial diseases are caused by
mutations in mitochondrial DNA (mtDNA) [1], a
16 596-base pair circular DNA that contains 13 genes
encoding subunits of the respiratory chain and 22 trans-
fer-RNA and two ribosomal-RNA genes for mitochon-
drial RNA translation. Genetically, mtDNA shows high
mutation rate, high copy number (thousands per cell) and
exclusively maternal transmission between generations.
In some individuals, only a fraction of mtDNAmolecules
are mutant (heteroplasmy); random distribution at cell
division during development and selection for or against
cells with high levels of mutant mtDNAs may lead toorized reproduction of this article is prohibited.
C472 Endocrinology and metabolismdifferent mutation loads in different cells and organs.
Mitochondrial dysfunction occurs beyond a certain level
of mutant mtDNA; this threshold presumably depends
on the energy requirement of each tissue.
Most pediatric mitochondrial diseases are caused by
defects of proteins encoded by nuclear genes that are
transported into mitochondria [2]. These mitochondrial
diseases are inherited in Mendelian fashion. Proteomic/
bioinformatic analyses predict more than 1 000 such
proteins [2,3]. Although complete inactivation of many
of themmay be prenatally lethal [4], they form a rich pool
of potential candidate genes for mitochondrial diseases.
For this review, we define mitochondrial diseases as
genetic conditions of the respiratory chain or preceding
steps of pyruvate oxidation and the Krebs cycle (Fig. 1).
The main function of mitochondria is ATP synthesis.
Proteins of mitochondrial and nuclear origin are
assembled in four of the five respiratory chain complexes.
Only Complex II contains exclusively nuclear-encoded
proteins. The respiratory chain receives energy-rich
hydrogen atoms from nicotinamide adenine dinucleotide
(NADH) or flavin-adenine dinucleotide (FADH), pro-
duced mainly in the Krebs cycle and from fatty acid
oxidation. Electrons from the hydrogen are passed
between complexes in the chain. Complexes I, III and
IV extrude protons from the mitochondrial matrix. Com-
plex IV (cytochrome oxidase) consumes oxygen to form
water. Complex V couples ATP synthesis to proton
reentry, powered by the electrochemical gradient.
Mitochondria are deeply integrated in cell biology, with
roles in urea, porphyrin [5] and steroid hormone synthesis
[6], apoptosis [7], calcium homeostasis [8] and free radical
production [9,10]. Changes in mitochondrial shape by
active fusion and fission are vital for cell function [11].
Secondary mitochondrial dysfunction occurs in diverse
situations like neurodegeneration [12,13] and aging
[14].The expanding clinical picture of
mitochondrial disease in children
Clinical evaluation is the key to decision making in chil-
dren with suspected mitochondrial disease. Clinical scor-
ing systems exist [15–17,18]. Some presentations alone
are strong indications for further testing for mitochondrial
disease (Tables 1 and 2A), as is the otherwise unexplained
coexistence of multiple compatible but less specific find-
ings (Table 2B). The known spectrum of mitochondrial
diseases in children, different from that in adults, has
regularly expanded in unexpected ways. The maxim
‘any tissue, any symptom, any age’ [19] is supported by
recent pediatric series [20,21]. A high level of suspicion is
necessary in patients with compatible findings, even ifopyright © Lippincott Williams & Wilkins. Unauthoaccompaniedby signsnotpreviouslydescribed inpediatric
mitochondrial diseases. Web-based catalogues listing
mitochondrial diseases and mutations include Online
Mendelian Inheritance in Man (OMIM) (http://
www.ncbi.nlm.nih.gov/sites/entrez?db=omim) and
mitomap (http://www.mitomap.org/); the latter has useful
links to patient organizations and research laboratories.The child with increased lactate
Lactic acidemia, a hallmark of mitochondrial dysfunction,
may be absent in proven mitochondrial disease or present
only during stress, and is highly variable in individual
patients [22]. Hyperlactatemia can also be caused by
hypoxia, hypoperfusion, shock, sepsis, cardiac failure
and inborn errors of metabolism, including some organic
acidemias, glycogen storage diseases, disorders of gluco-
neogenesis and of fatty acid oxidation, treatment of which
differs from that for mitochondrial diseases. Elevated
blood lactate is a common artefact if a tourniquet is used
for phlebotomy, causing venous stasis and lactate accumu-
lation from erythrocyte glycolysis, or if the child struggles
during sampling. In children with elevated lactate, but
otherwise at low clinical risk for mitochondrial disease, we
sample on several occasions, if possible before and after
meals and through an indwelling catheter, permitting
blood sampling at rest and determination of other energy
substrates (pyruvate, glucose, amino acids including ala-
nine, ketone bodies). Cerebrospinal fluid (CSF) lactate
level is amore reliable diagnosticmarker formitochondrial
disease than is blood, especially in patients with brain
involvement [23,24]; proton magnetic resonance spec-
troscopy [25] allows noninvasive detection of elevated
cerebral lactate and other relevant compounds.
Tools for further investigation
In patients strongly suspected of mitochondrial disease,
further investigation involves biochemical assays of the
respiratory chain [25] and/or molecular studies.
Direct measures of respiratory chain function include
polarographic studies of mitochondrial respiration on
fresh tissue and spectrophotometric assays of the respir-
atory chain complexes, feasible on small samples of
frozen tissue. Both mtDNA and nuclear-determined
respiratory chain defects may be tissue-specific; hetero-
plasmy of mtDNA mutations and tissue-specific levels of
nuclear gene products [26,27] partially explain this
phenomenon. Study of clinically affected tissues provides
the highest yield of informative results. Careful attention
to rapid freezing or, wherever available, to rapid testing of
fresh tissue, reduces artefactual decreases of respiratory
chain activities.
In blue native polyacrylamide gel electrophoresis (BN-
PAGE) of respiratory chain complexes [28–30], the fiverized reproduction of this article is prohibited.
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(a) Mitochondrial morphology. The left side of the figure shows the structural features of normal mitochondria, including the two membranes and an
inner matrix. The outer membrane is quite permeable. The inner mitochondrial membrane has a distinct chemical composition. Its folds (cristae)
protrude into the matrix, increasing the surface area. This membrane is less permeable but contains many metabolite transporters (not shown) and
houses the respiratory chain. In mitochondrial disease (right), the changes are highly variable and are shown in composite. Mitochondria may proliferate,
change in size (megamitochondria) or shape (elongated, branched), have hypertrophied or bizarrely-shaped cristae, or may contain crystal-like
(paracrystalline) inclusions within the matrix. (b) Energy metabolism can be divided into circulating, cytoplasmic and mitochondrial compartments;
mitochondrial metabolism is further divided into pre-Krebs, Krebs and respiratory chain components. The degradation products of fatty acids and of
glucose enter the Krebs cycle at different sites, which are used therapeutically in some pre-Krebs cycle mitochondrial diseases [e.g. a high-fat,
ketogenic diet in some cases of pyruvate dehydrogenase (PDH) deficiency]. For simplicity, amino acids are not shown; different amino acids enter the
Krebs cycle at various points. In mitochondrial diseases, there is a paradoxical increase of energy metabolites and of reduced nucleotides
[(nicotinamide adenine dinucleotide (NADH), flavin-adenine dinucleotide (FADH)] but a deficiency of ATP production, despite normal oxygen
availability. The cytoplasmic NADH/NAD ratio, a measure of redox potential, can be roughly estimated from the ratio of circulating lactate to pyruvate;
intramitochondrial redox potential, from the plasma 3HB/AcAc ratio. High ratios are frequent in mitochondrial diseases. Circulating ketone bodies are
derived mainly from liver, by unidirectional hepato-specific ketogenesis, but may also arise from other tissues which have a high concentration of
AcCoA, by reversal of the enzyme that normally activates AcAc for intracellular metabolism; this may be substantial in some mitochondrial diseases.
Some NADH and FADH are produced from glycolysis (not shown) and beta oxidation (b-ox), but the Krebs cycle is the cell’s main source of these
compounds. The three Krebs cycle steps discussed in the text are shown. Distinct isozymes of succinate-CoA ligase (SUCL) catalyze the synthesis of
either guanosine triphosphate (GTP) or ATP. The respiratory chain is composed of five multisubunit complexes as shown and is the main site of cellular
oxygen consumption, ATP synthesis and (not shown) oxygen radical production. Electrons fromNADH are donated to Complex I, which passes them to
coenzymeQ. FADH-containing molecules include succinate dehydrogenase (SDH, that is Complex II) and electron transfer flavoprotein (ETF) and ETF
dehydrogenase (ETFDH). They donate electrons directly to CoenzymeQ (CoQ). Electrons pass to Complex III, cytochrome c (c) and finally to Complex
IV (cytochrome oxidase), the main site of cellular oxygen consumption, forming water. Electron transport is accompanied by the extrusion of protons
(Hþ) from the matrix by complexes I, III and IV, creating an electrochemical gradient that is used by Complex V to catalyze most of cellular ATP synthesis.
The direct relationship between oxidation, proton gradient formation and ATP synthesis is termed ‘coupling’. AcAc, acetoacetate; BNG, blue native gel;
Dx, diagnosis; MD, mitochondrial disease; RRF, ragged red fibers.mitochondrial respiratory chain complexes are resolved
electrophoretically but remain intact and catalytically
active. Histochemical staining and immunodetection of
respiratory chain subunit proteins allows detection ofopyright © Lippincott Williams & Wilkins. Unauthboth defective enzyme function and reduced amounts
of respiratory chain complexes. BNG-PAGE may be less
influenced than functional studies by suboptimal tissue
conservation and has substantial diagnostic yield [21,31].orized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Table 2 Clinical and biochemical findings of mitochondrial disease in children
(A) Signs and symptoms highly suggestive of a mitochondrial diseasea,b (B) Signs and symptoms compatible with mitochondrial diseaseb
Neurologic General
Episodic or progressive mental regression Failure to thrive; short stature
Episodic neurological symptoms of unknown cause Fatigue
Cerebral stroke-like episode with nonvascular distribution of lesions Neurologic
Unexplained brainstem dysfunction (rapid onset,
hypoventilation or hyperventilation, drooling, oculomotor
changes, altered level of consciousness, hypothermia or
hyperthermia, hypotension or hypertension)
Progressive or static developmental delay; encephalopathy
Cerebral atrophy
Seizures, especially myoclonic




Hypotonia or progressive spasticity
Leukodystrophy
Exercise intolerance with or without rhabdomyolyis
Migraine
Other
Ophthalmologic (optic atrophy, cataracts), pigmentary retinal
degeneration
Sensorineural hearing loss; aminoglycoside-induced deafness
Sideroblastic anemia
Dermatological (hypertrichosis, pili torti, subcutaneous lipomas)
Endocrine (hypoparathyroidism, glucose intolerance, diabetes)
Dilated cardiomyopathy
Recurrent vomiting
Unexplained liver disease (fatty liver, hepatocellular lysis, cirrhosis)
Pancreatic insufficiency
Renal (tubular acidosis; renal Fanconi syndrome; unexplained
glomerulopathy; nephrotic syndrome)
Brainstem ( basal ganglia) involvement in MRI (Leigh syndrome-like)
Muscular
Myopathy with presence of ragged red fibers
Cardiovascular
Unexplained hypertrophic cardiomyopathy
Arrhythmia of unknown cause: heart block,
Wolff–Parkinson–White, and others
Ophthalmologic
External ophthalmoplegia with or without ptosis
Sudden or insidious optic neuropathy
Gastroenterologic
Unexplained liver failure (especially if valproate-related),
Reye-like syndrome
Severe intestinal dysmotility, chronic pseudoobstruction
Clinical biochemistry
Persistent elevation of blood lactate
Episodes of acidosis, ketosis or hyperlactatemia, exceeding
the expected physiological concentration; postprandial ketosis
Characteristic MRS spectra (lactate); e.g. succinate in succinate
dehydrogenase deficiency
MRS, magnetic resonance spectroscopy.
a The unexplained occurrence of one or more of these signs places mitochondrial disease high on the list of possible diagnoses.
b The suspicion of a mitochondrial disease increases with the presence of each additional unexplained sign from Table 2B, especially if they arise from
different organs (multisystemic), or if one or more signs from Table 2B occur with sign(s) from Table 2A.Most patients with mitochondrial disease do not cur-
rently have a precise molecular diagnosis. Molecular
testing as an initial step has low yield because of the
large number of different mitochondrial diseases; this
may change asmolecular tests incorporate large numbers
of genes. If there is clinical suspicion of a disease fre-
quently caused by readily testable mutations [mitochon-
drial myopathy, encephalopathy, lactic acidosis, and
stroke (MELAS), maternal inherited Leigh syndrome
(MILS), etc.] or if the patient is from an ethnic group
with a strong founder effect and has suggestive signs,
molecular testing is indicated. Testing for common
mutations and complete mtDNA sequencing are clini-
cally available. For mtDNA mutations not previously
known as pathogenic, it may be difficult to distinguish
between true causal mutations, functionally neutral
variants and technical artefacts [32].
Fasting and dietary loading tests have limited diagnostic
usefulness and can precipitate crises in some patients.
They are useful in selected patients to determine and
monitor diet and other treatments. Exercise testing in
patients with myopathic mitochondrial disease character-
istically reveals low endurance and low oxygen utilization
[33], but requires a level of collaboration rare in children
with mitochondrial disease.opyright © Lippincott Williams & Wilkins. UnauthCurrent protocols of investigation
Our current approach to further investigation is summar-
ized in Fig. 2. In deciding whether to investigate a patient,
we consider clinical phenotype, biochemical findings
(mean plasma lactate and pyruvate, urinary organic acids,
including lactate and Krebs cycle metabolites, plasma
amino acids, etc.). CSF lactate and pyruvate levels and
neuroimaging, includingmagnetic resonance spectroscopy
[34], are obtained in childrenwith neurological symptoms
and suspected mitochondrial disease.
Clinical suspicion of a specific mitochondrial syndrome
calls for testing in an appropriate sample obtained by the
least invasive means. For example, common MELAS,
Leber’s Hereditary Optic Neuropathy (LHON) and
neurogenic weakness, ataxia and retinitis pigmentosa
(NARP)/MILS mtDNA mutations are detectable in leu-
kocyte DNA. mtDNA deletions are detectable in blood
in Pearson syndrome, but otherwise are tissue-specific,
for example, muscle in Kearns–Sayre syndrome. Infan-
tile liver failure suggests hepatic mtDNA depletion; liver
mtDNA quantification is a logical first step.
Muscle biopsy is performed in myopathic patients.
The presence of ragged red fibers in a mosaic pattern,orized reproduction of this article is prohibited.
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Figure 2 Diagnostic evaluation in children suspected of mitochondrial disease is governed by clinical parameters
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It is impossible to summarize the investigation of the entire spectrum of patients with mitochondrial disease in a single algorithm, but the approach to
most patients with mitochondrial disease who are not acutely ill resembles this. (a) Clinically distinct syndromes (see Table 1) or compatible signs in
patients from ethnic groups with strong founder effects and known mutations [e.g. Leigh disease in French Canadians (LRPPRC), dilated
cardiomyopathy and cerebellar ataxia in Hutterites (DNAJC19), encephalomyopathy in patients from the Faroe islands (SUCLA2), liver disease
and neuropathy in Navajo Indians (MPV17), infantile spinocerebellar ataxia in Finns (Twinkle), etc.]. (b) The most clinically affected tissue (muscle, liver)
is chosen for biopsy; studies involve light and electron microscopy, spectrophotometry and blue native gel (BNG), CoQ10 assay (particularly in
patients with ataxia or nephrotic syndrome) and possibly mtDNA quantification if clinically suggested or if multiple complex deficiencies are found on
spectrophotometry or BNG. (c) Further testing depends on whether single or multiple complex deficiencies are found and is individualized in
collaboration with an experienced diagnostic laboratory. 3HB, 3-hydroxybutyrate; AcAc, acetoacetate; b-ox; beta oxidation; ETF, electron transfer
flavoprotein; ETFDH, ETF dehydrogenase; GDP, guanosine 5’-diphosphate; GTP, guanosine triphosphate; NADH, nicotinamide adenine dinucleotide;
PDH, pyruvate dehydrogenase; SDH, succinate dehydrogenase.juxtaposed with normal-appearing fibers, strongly
suggests mtDNA disease. Frozen tissue obtained at
biopsy can be used for mutation detection. If ragged
red fibers are not observed, respiratory chain spectropho-
tometry and BN-PAGE are performed. Coenzyme Q
(CoQ) is assayed in both cases.
Skin biopsy for fibroblast culture is performed in all
patients. We obtain pyruvate dehydrogenase (PDH)
and pyruvate carboxylase assays, biochemical respiratory
chain studies and BN-PAGE analysis. Skin biopsy is
minimally invasive and yields can reach 50% when
spectrophotometry and BN-PAGE are combined
[21,30,35]. In some patients without molecular diag-
nosis, markedly decreased fibroblast activity may pro-
vide a marker for prenatal diagnosis (after discussion in
advance with an experienced laboratory) and for gene
discovery [36]. If fibroblast studies are inconclusive,opyright © Lippincott Williams & Wilkins. Unauthomuscle and/or liver biopsies are performed according
to clinical judgement.
In acute or rapidly progressive illness, the intensity of
investigations is accelerated. The potential risk that the
stresses associated with imaging or biopsies may
occasionally precipitate neurological or acidotic crises is
weighed against the need for rapid diagnosis.
Other metabolic diseases, including congenital disorders
of glycosylation, overlap clinically with mitochondrial
diseases and should be excluded in the absence of a
conclusive diagnosis.
Biochemical and clinical phenotypes and molecular
causes do not always correlate. For example, Leigh
syndrome (MIM 256000) can occur in isolated
deficiencies of any of the respiratory chain complexes,rized reproduction of this article is prohibited.
CDisorders of mitochondrial function Debray et al. 477pyruvate carboxylase, PDH or CoQ synthesis. Conver-
sely, complex I-deficient or IV-deficient patients, for
instance, can also present with encephalomyopathy,
cardiomyopathy, neonatal acidosis or in other fashions.
Different mutations in a single gene can cause divergent
symptoms (e.g. some BCS1L mutations can cause
encephalopathy–tubulopathy [37], neonatal lactic
acidosis–liver hemosiderosis [38]; others cause isolated
deafness–brittle hair with pili torti (Bjo¨rnstad
syndrome)[39]). In general, siblings with nuclear-
encodedmitochondrial diseases tend to have similar types
of symptoms.Molecular bases of mitochondrial disease in
pediatrics: unraveling the genetic complexity
of mitochondrial disease
Current rates of discovery are unprecedented in mito-
chondrial biology and mitochondrial diseases (Table 3).
Mitochondrial diseases are now classified not only as
nuclear or mtDNA-related, but also by pathophysiology.
Respiratory chain deficiency can arise from deficiency
of structural respiratory chain proteins or accessory
molecules like CoQ, or abnormalities of respiratory
chain complex assembly, mtDNA replication or main-
tenance, mtRNA translation or mitochondrial dynamics
(fusion/fission; mobility). Other mechanisms may be
discovered.Deficiencies of respiratory chain components and
cofactors
Many mutations in the 13 structural mtDNA-encoded
respiratory chain subunits are well known to cause
LHON and NARP/MILS (Table 1); other mutations
are regularly being identified. At least 74 nuclear genes
encode respiratory chain subunits; mutations in only 15 of
them are described in mitochondrial diseases.
Deficiencies of complex I [40] or complex IV [41] are
the commonest isolated defects, perhaps because of the
many structural and assembly peptides required by these
complexes. Mutations in NDUFA1, the first X-linked
gene associated with complex I deficiency, were
described in boys with Leigh syndrome or myoclonic
epilepsy [42].
CoQ funnels electrons from complexes I and II to com-
plex III. CoQ deficiency, primary or secondary, may
respond to replacement therapy. Mutations in APTX
[43,44] and ADCK3 [45,46] were recently found in
CoQ deficiency with ataxia. Mutations in three genes
of CoQ biosynthesis, COQ2 [47], PDSS2 [48] and PDSS1
[49] were reported in patients with severe infantile mito-
chondrial syndromes and tissue CoQ10 deficiency.
Nephrotic syndrome has been reported in several
patients with COQ2 mutations [50].opyright © Lippincott Williams & Wilkins. UnauthRespiratory chain complex assembly deficiencies
Mutations in assembly factors are the commonest cause
of isolated complex I deficiency [51]; three were recently
described in patients with infantile encephalopathy and
lactic acidosis [51,52,53]. Assembly factor defects are
also the main cause of complex IV deficiency (SURF1,
SCO1, SCO2, COX10, COX15; possibly LRPPRC) [31,54])
and are reported for complexes III [37] and V [55].
Disorders of mtDNA replication and maintenance
In these ‘disorders of intergenomic communication’ [56],
nuclear gene defects cause mtDNA abnormalities. These
are detected in affected tissues as mtDNA depletion and/
or accumulation of multiple different mtDNA deletions,
resulting in deficiency of multiple respiratory chain com-
plexes. Mitochondria possess a complete DNA replica-
tion/maintenance system, including DNA polymerase
gamma (POLG), a helicase (Twinkle) and other
enzymes, requiring a continuous supply of deoxynucleo-
tides. mtDNA depletion/multiple deletions syndromes,
initially reported in adults with progressive external
ophthalmoplegia (PEO) or cerebellar ataxia [57,58], are
now recognized as major causes of neonatal/infantile liver
failure and infantile encephalomyopathy [59].
Causal mutations are documented in 12 nuclear genes.
Three of these genes are directly implicated in mtDNA
replication: POLG (both subunits) [58,60] and Twinkle
[61]; POLG1 mutations cause Alpers–Huttenlocher syn-
drome (autosomal recessive infantile hepatic failure, epi-
lepsy and encephalopathy). Seven genes are implicated
in regulating mitochondrial deoxynucleotide pools
[27,62–65,66,67,68,69], and two genes function by
unknown mechanisms: MPV17, which causes isolated
liver failure [69] and OPA1 (see below).
mtRNA translation defects
The genetic code, tRNAs and rRNAs of mitochondria
differ from those of the cytosol. mtDNA tRNA mutations
cause mitochondrial disease (Table 1). There are over 50
knownnuclear-encodedmitochondrial ribosomal proteins,
tRNA maturation enzymes and translation initiation,
elongation and termination factors. In seven (three in
the last year), mutations have been identified in human
mitochondrial diseases: three translationelongation factors
[70–72], two ribosomal proteins [73,74] and two enzymes
of tRNA maturation [75,76]. Clinical presentations
include fulminant neonatal lactic acidosis, infantile
encephalopathy, hypertrophic cardiomyopathy with ence-
phalomyopathy, and leukoencephalopathy with brain
stem and spinal cord involvement and lactic acidosis.
Defects of mitochondrial protein import
Two known mitochondrial diseases are attributable
to abnormal protein import. In Mohr–Tranebjaerg
(X-linked deafness–dystonia) syndrome, deafness isorized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CDisorders of mitochondrial function Debray et al. 479followed by progressive neurological troubles, including
dystonia and optic atrophy [77,78]. Mutation of
DNAJC19, encoding a putative mitochondrial import
protein, causes autosomal recessive dilated cardiomyo-
pathy with ataxia [79].
Mitochondrial biogenesis, fusion, fission and mobility
Dynamin-type guanosine triphosphatases are essential
for mitochondrial mobility and exchange. Mutations in
dynamin-like genes were first described in autosomal
dominant optic atrophy (OPA1) and Charcot-
Marie-Tooth neuropathy types 2A and 4A [11,80–82].
Mitochondrial fusion defects exert general effects on
mitochondrial function. The mitochondrial fusion-
related gene OPA1 is implicated in apoptosis [83,84]
and oxidative phosphorylation [85], andmultiplemtDNA
deletions are found in muscle of some patients [86],
suggesting that the OPA1 protein also influences mtDNA
maintenance [87].
In an infant with lactic acidosis and increased very long
chain fatty acids, Waterham et al. [88] demonstrated a
combined defect of mitochondrial and peroxisomal fis-
sion, due tomutation inDLP1, which encodes a dynamin-
like protein. Despite severe lactic acidosis, respiratory
chain assays were normal in muscle and fibroblasts. The
authors proposed examination of mitochondrial
morphology in cultured cells as a new diagnostic tool.Krebs cycle
Three successive steps of this intramitochondrial path-
way provide unexpected phenotypes. Deficiencies of the
guanosine 5’-diphosphate (GDP)-specific and ADP-
specific succinate-CoA ligase (SUCL) enzymes are clini-
cally distinct (Table 3). Succinate dehydrogenase (Com-
plex II) subunit A deficiency can cause typical autosomal
recessive mitochondrial disease, including Leigh disease
[89], whereas mutations of subunits B, C and D predis-
pose to pheochromocytoma in a dominant fashion [90–
92]. Fumarase deficiency can cause autosomal recessive
encephalopathy or autosomal dominant tumors (uterine
fibromas, renal cancer) [93], the latter possibly by affect-
ing hypoxia-inducible factor metabolism [94].Prognosis and management
Prognostic counseling is difficult because of high inter-
patient variability. Empirical data clearly show higher risk
for symptomatic LHON and Alpers disease in men [95]
and for valproate hepatotoxicity in mitochondrial disease
in general and Alpers disease in particular [95,96]. Inter-
esting research has identified modifier loci for LHON in
mtDNA [97] and on the X chromosome [98], but as yet
does not allow for precise counseling. Reproductive
genetic counseling is challenging for heteroplasmicopyright © Lippincott Williams & Wilkins. UnauthmtDNA disorders because marked, unpredictable differ-
ences of mutantmtDNA load occur betweenmothers and
offspring [99]. Empirical figures are available for trans-
mission and prognosis in some mtDNA-related diseases
[100,101]. Preimplantation diagnosis [102] and other
reproductive technologies hold promise for the future
[10,33].
Two recent studies [21,103] addressed long-term out-
come in pediatric mitochondrial diseases, showing that,
despite high mortality and morbidity, some patients with
mitochondrial disease can become clinically stable and
that prognosis is not uniformly poor. A scale for severity of
disease course has been proposed [104].
Nonetheless, effective management of mitochondrial
diseases is a major challenge in pediatrics. Few con-
trolled therapeutic trials exist [105]. Many pediatric
mitochondrial diseases, like Leigh disease, predispose
to acute acidotic or neurologic crises that often but not
always coincide with periods of physical, nutritional or
infectious stress. We have a strong clinical impression
that avoidance of extremes of nutrition (fasting, exces-
sive consumption) or physical exertion, and rapid sup-
portive treatment of intercurrent illness can improve
outcome. We avoid invasive or stressful testing during
and immediately after crises, during which patients
seem to be particularly susceptible to further episodes.
Many physicians use ‘mitochondrial cocktails’ of unpro-
ven efficiency, containing vitamins and other com-
pounds [10,33]. Importantly, primary or secondary
[106] CoQ deficiency can respond to oral CoQ10
supplementation [107,108], though some patients
progress despite treatment [109]. CoQ10 may also sca-
venge free radicals [10]. PDH-deficient patients may
benefit from thiamine supplementation, a ketogenic
diet or dichloroacetate administration [110–112]. The
lactic acidosis of biotinidase deficiency is cured by biotin
administration. Peripheral neuropathy limits chronic
dichloroacetate use [113]. Dichloroacetate can lower lac-
tate level nonspecifically in mitochondrial disease [114]
and may be useful for short treatment of severe acidotic
episodes. Recent observations in a small number of
patients have suggested that defective ATP-dependent
cerebral folate transport may result in reduced CSF
5-methyltetrahydrofolate levels in some patients with
mitochondrial disease, with detectable clinical improve-
ment with oral folinic acid supplementation [115,116].
Potential future approaches tomitochondrial disease treat-
ment have recently been reviewed [10,33].Conclusion
In the past year, there has been an unprecedented pace of
gene discovery for mitochondrial disease. With a high
level of clinical alertness and an organized diagnosticorized reproduction of this article is prohibited.
C480 Endocrinology and metabolismapproach, most mitochondrial diseases can be confirmed
early in their course and many can benefit from precise
molecular diagnosis. Supportive treatment and genetic
counseling are important. Few specific treatments for
mitochondrial diseases are available and their develop-
ment is a major challenge for research.Acknowledgements
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